Aemetis (NASDAQ:AMTX – Get Free Report) released its quarterly earnings results on Thursday. The specialty chemicals company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04, Zacks reports. The firm had revenue of $43.31 million during the quarter, compared to the consensus estimate of $72.07 million.
Here are the key takeaways from Aemetis’ conference call:
- Aemetis’ dairy RNG segment reached positive segment net income and EBITDA in Q4, produced ~405,000 MMBtus in 2025 (12 digesters) with Q4 biogas net income of $12.2M and 61% production growth, and management expects strong cash-flow growth over the next four years as expansion and 45Z monetization proceed.
- The Keyes ethanol plant’s mechanical vapor recompression (MVR) upgrade — already >50% spent and fully financed — is projected to cut natural gas use ~80%, lower carbon intensity, and add roughly $32 million of annual plant cash flow with contributions beginning in Q3–Q4 2026.
- Policy and credit tailwinds are strengthening revenue visibility: LCFS credit prices have risen ~60% recently and the February 4 Treasury guidance on Section 45Z positions the company to capture additional production tax credits once the DOE’s GREET spreadsheet and calculated emissions value letters are issued.
- Capital plan: MVR and a $27M H2S contract are fully financed, while management expects roughly $70M more for digester build-out (overlapping into 2027) and plans to use long‑term (20‑year) project financings for further expansion.
- The India subsidiary generated $29.7M in 2025 revenue with ~80M gallon biodiesel capacity and management is pursuing an IPO to fund expansion into CBG and sustainable aviation fuel, though market timing and execution remain uncertain.
Aemetis Price Performance
NASDAQ:AMTX traded up $0.12 during mid-day trading on Friday, reaching $2.04. 1,380,746 shares of the company’s stock traded hands, compared to its average volume of 890,586. The company has a 50 day moving average price of $1.54 and a 200-day moving average price of $1.91. The firm has a market capitalization of $134.72 million, a price-to-earnings ratio of -1.26 and a beta of 2.61. Aemetis has a 12-month low of $1.22 and a 12-month high of $3.66.
Institutional Investors Weigh In On Aemetis
Analysts Set New Price Targets
AMTX has been the topic of a number of research analyst reports. Loop Capital set a $1.75 target price on Aemetis in a research note on Thursday. Ascendiant Capital Markets lowered their target price on shares of Aemetis from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 19th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aemetis in a research note on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.19.
Read Our Latest Analysis on AMTX
About Aemetis
Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.
Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.
Featured Stories
- Five stocks we like better than Aemetis
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.
